Pfizer's Braftovi Significantly Extends Survival in Advanced Colorectal Cancer
A late-stage trial found that a Pfizer combination therapy, including chemotherapy, cetuximab, and Braftovi, doubled survival time for patients with aggressive colorectal cancer with BRAF V600E mutation, setting a new standard of care for this subset of patients.